Novartis AGNVSNYSE
Loading
EBITDA as a percentage of revenue
3Y CAGR
+7.5%/yr
vs -6.3%/yr prior
5Y CAGR
+4.0%/yr
Recent acceleration
Acceleration
+13.8pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
3 yr
Consecutive growthStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 41.94% | +4.7% |
| 2024 | 40.05% | +2.4% |
| 2023 | 39.12% | +15.8% |
| 2022 | 33.78% | -51.9% |
| 2021 | 70.30% | +103.8% |
| 2020 | 34.49% | +7.5% |
| 2019 | 32.08% | -26.9% |
| 2018 | 43.90% | +30.6% |
| 2017 | 33.61% | +14.1% |
| 2016 | 29.47% | - |